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RESEARCH ARTICLE
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Merja Suominenb and Kaisu Pitk€al€ab
aHome Care, City of Helsinki, Finland; bUniversity of Helsinki, Department of General Practice and Helsinki University Hospital, Unit of
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ABSTRACT
Objective: This study aims to assess potentially severe class D drug–drug interactions (DDDIs) in
residents 65 years or older in assisted living facilities with the use of a Swedish and Finnish
drug–drug interaction database (SFINX).
Design: A cross-sectional study of residents in assisted living facilities in Helsinki, Finland.
Setting: A total of 1327 residents were assessed in this study. Drugs were classified according to
the Anatomical Therapeutic Chemical (ATC) classification system and DDDIs were coded accord-
ing to the SFINX.
Main outcome measures: Prevalence of DDDIs, associated factors and 3-year mortality among
residents.
Results: Of the participants (mean age was 82.7 years, 78.3% were females), 5.9% (N¼ 78) are at
risk for DDDIs, with a total of 86 interactions. Participants with DDDIs had been prescribed a
higher number of drugs (10.8 (SD 3.8) vs. 7.9 (SD 3.7), p< 0.001). A larger proportion of residents
with DDDIs suffered from rheumatoid arthritis or osteoarthritis than those not exposed to DDDIs
(24.7% vs. 15.4%, p¼ 0.030). The most frequent DDDIs were related to the concomitant use of
potassium with amiloride (N¼ 12) or spironolactone (N¼ 12). Carbamazepine (N¼ 13) and metho-
trexate (N¼ 9) treatments were also frequently linked to DDDIs. During the follow-up, no differen-
ces in mortality emerged between the participants exposed to DDDIs and the participants not
exposed to DDDIs.
Conclusions: Of the residents in assisted living, 5.9% were exposed to DDDIs associated with the
use of a higher number of drugs. Physicians should be trained to find safer alternatives to drugs
associated with DDDIs.
KEY POINTS
Potentially severe, class D drug–drug interactions (DDDIs) have been defined in the SFINX data-
base as clinically relevant drug interactions that should be avoided.
 Of the residents in assisted living, 5.9% were exposed to DDDIs that were associated with
the use of a higher number of drugs.
 The most frequent DDDIs were related to the concomitant use of potassium with amilor-
ide or spironolactone. Carbamazepine and methotrexate were also linked to DDDIs.
 No difference in mortality was observed between residents exposed to DDDIs and resi-
dents not exposed to DDDIs.
ARTICLE HISTORY
Received 25 August 2014
Accepted 7 April 2016
KEYWORDS
Assisted living; drug–drug
interactions; Finland; general
practice; mortality
Introduction
Older people in assisted living facilities are prone to
potentially severe drug–drug interactions (DDIs) due to
comorbidities and the use of a higher number of
drugs.[1] Potentially severe DDIs correspond to class D
interactions (DDDIs) according to the Swedish, Finnish
Interaction X-referencing (SFINX) database. They may
lead to negative clinical outcomes and should always
be avoided. They have received increasing attention in
older populations since multiple medication use is
becoming more common in managing diseases. DDIs
have been studied in hospital and outpatient settings,
and from drug registers. Register-based studies are the
most common, reporting DDI prevalence rates of
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15–26%,[2–4] whereas studies conducted in commu-
nity settings show prevalence of 26.5–63%.[5,6]
Prevalence rates also vary in hospital settings, includ-
ing wards (57.8%) [7] and emergency departments
(0.7%).[8] The definition for DDIs has varied from one
study to another depending on the applied assessment
methods, populations and study settings, thus resulting
in a wide range of prevalence. This makes it difficult to
compare DDIs between studies. Few researchers have
evaluated the severity of DDDIs. To our knowledge,
limited studies have additionally examined the preva-
lence rates of DDDIs among institutionalized residents
(4.8%),[1] who are most susceptible to the use of a
higher number of drugs [9] and, therefore, also to
DDDIs.[3–6] Irrespective of the setting, DDDIs have
been evaluated to be less common (0.7–16%).[1,3–6,8]
DDDIs have been shown to associate with patients’
increasing age,[4,10,11] female gender,[12] the use of
a higher number of drugs [3–6,11–13] and cardiovas-
cular diseases.[12] The most frequently reported
DDDIs have been associated with the use of anticoa-
gulants,[10,13] potassium sparing-diuretics, potassium
supplements, or ACE inhibitors [1,14] and carbamaze-
pine.[1] DDDIs are related to adverse events, an
increased number of hospitalizations [14,15] and
higher healthcare costs.[15]
DDDIs can be predicted and avoided through edu-
cation and interventions.[3,16,17] Several studies have
shown that physicians are only aware of a minority of
DDDIs.[16,18]
Although several large register-based studies have
reported DDDI prevalence, few studies to date have
examined the clinical outcomes of DDDIs in frail, older
populations prone to using a higher number of drugs.
We hypothesized that DDDIs are associated with the
use of a higher number of drugs, comorbidities and
increased mortality. The aim of this study was to
describe (1) the prevalence of DDDIs according to the
SFINX database among older people living in residen-
tial care facilities and associated characteristics of resi-
dents and (2) to compare the mortality of residents
with and without DDDIs.
Materials and methods
Settings and study population
A cross-sectional study was carried out among older
people in all residential care facilities in the cities of
Helsinki and Espoo, Finland, based on data collected in
February 2007 as part of a larger project investigating
nutritional status and nutritional care.[19] The study
includes all 36 and 33 residential care units located in
Helsinki and Espoo, respectively. Of the eligible resi-
dents (N¼ 2188), 67% (N¼ 1475) consented to partici-
pate in the study. Nonparticipants either refused (28%,
N¼ 608) or were residents in temporary respite care
(5%, N¼ 105) (Figure 1). Of all residents, 148 were
excluded due to complete medication or mortality
data being unavailable. Data were thus available for a
2188 eligible residents
1475 residents
(67%)
1327 residents analyzed
(90%)
78 participants with 
DDDI
(5.9%)
1249 participants without
DDDI
(94.1%)
608 refused to participate (28%)
105 temporary respite residents (5%)
148 excluded due to incomplete data 
(medication data or mortality)
Figure 1. Flow chart of the study.
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total of 1327 residents. The assisted living facilities in
Helsinki and Espoo provide round-the-clock care with a
registered nurse in charge, similar to traditional nursing
homes. However, the environment in assisted living
units is more home-like than in traditional nursing
homes. Resident characteristics are similar to those in
traditional nursing homes.[19]
Assessments
Health status data, demographic factors, drug use, and
diagnoses were retrieved from medical charts by
nurses working in care units, who had received specific
training by researchers for gathering the medical data.
All assessments and data gathering were performed
during a single day (31 March 2007). Mortality dates
were retrieved from the Finnish central registers until 6
July 2010.
The Charlson comorbidity index was used, taking
into account the number and severity of comorbid con-
ditions.[20] The Clinical Dementia Scale (CDR) was used
to assess the cognitive state of the participants.[20]
Dependency in activities of daily living (ADL) was
defined as ‘‘requiring at least prompting or assistance in
dressing, hygiene, managing personal effects, or requir-
ing much help with personal care, often involving
incontinence’’ in the ‘‘personal care’’ item of the Clinical
Dementia Rating scale (CDR class 1 or higher).[21]
Residents were classified using the Mini Nutritional
Assessment (MNA) test,[22] in the following ways: (i)
good nutritional status, MNA score 24–30, (ii) risk of
malnutrition, MNA score 17–23.5, and (iii) malnutrition,
MNA score <17.
Psychological well-being (PWB) was assessed using
the PWB score,[23] which is derived from six questions:
(1) ‘‘Are you satisfied with your life?’’ (yes/no), (2) ‘‘Do
you have zest for life?’’ (yes/no), (3) ‘‘Do you have plans
for the future?’’ (yes/no), (4) ‘‘Do you feel needed?’’ (yes/
no), (5) ‘‘Do you feel depressed?’’ (seldom or never/
sometimes/often or always), and (6) ‘‘Do you suffer from
loneliness?’’ (seldom or never/sometimes/often or
always). The score is created so that each question rep-
resents 0 (‘‘no’’ in questions 1–4, ‘‘often or always’’ in
questions 5 and 6), 0.5 (‘‘sometimes’’ in questions 5 and
6) or 1 point (‘‘yes’’ in questions 1–4, ‘‘seldom or never’’
in questions 5 and 6). The score is calculated by dividing
the total points with the number of questions answered
by the participant. A score of 1 thus represents the best
and 0 the poorest PWB. A difference of 0.08–0.1 in scale
can be considered clinically meaningful. The score has
been validated among older people.[23]
The use of medications was assessed as a point-
prevalence during the assessment day. Residents were
classified as regular drug users if their medical charts
indicated a regular sequence for drug dosage. Only
drugs used on a regular basis were taken into account.
We did not have information on how often the partici-
pants used pro re nata drugs so they were excluded.
All drugs were classified according to the Anatomical
Therapeutic Chemical (ATC) classification system (WHO
Collaborating Center for Drug Statistics Methodology
2010).
The SFINX computerized database system [24] was
used for assessing DDDIs. SFINX is a commercial
drug–drug interaction database and software providing
short and concise evidence based information concern-
ing the consequences of and recommendations for
18,000 drug combinations. It has been commonly
used by Finnish doctors since 2005 and is updated
four times a year by Medbase Ltd in Turku, Finland,
the Karolinska Institute Department of Clinical
Pharmacology in Stockholm, and the Stockholm
County Council, Sweden. Interactions are classified
according to their clinical significance (A–D) and docu-
mentation level (0–4), where A indicates a clinically
insignificant interaction and D a clinically significant
interaction that should be avoided. The database does
not automatically alert the physician; potential interac-
tions must be checked individually.[24]
Outcomes
The number of DDDIs and mortality were the main
outcomes. We considered comorbidities, different med-
ical conditions, the number of medications, function-
ing, nutrition and PWB to be potential associates and
confounders of the main outcome measures.
Statistical methods
For data analysis, the Number Cruncher Statistical
System (NCSS) (www.ncss.com) and SPSS 12.0.1 (SPSS
Inc., Chicago, IL) software programs were applied.
Differences in proportions were tested with the X2 –
test. The Mann–Whitney U-test was used for evaluating
non-normally distributed continuous variables in this
study. In all analyses, p< 0.05 was considered statistic-
ally significant. The Helsinki University Central Hospital
Ethics Committee approved the study protocol.
Informed consent was acquired from each participant.
Results
Residents’ mean age was 82.7 years (SD 7.8), and
78.3% were females. A mean of 8.0 (SD 2.9) drugs
were administered regularly to each resident.
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Of the participants, 5.9% (N¼ 78) run the risk of
DDDIs, with a total of 86 interactions. Eight residents
were susceptible to two DDDIs.
More often than other residents, those exposed to
DDDIs had been prescribed a higher number of drugs
(10.8 (SD 3.8) vs. 7.9 (SD 3.7), p< 0.001) and had arth-
ritis. Residents exposed to DDDIs showed no significant
differences in demographic characteristics, common
medical conditions, the Charlson comorbidity index,
malnutrition, cognitive impairment, mobility, functional
ability or PWB compared with those not exposed to
DDDIs (Table 1). An association trend was observed
between cardiovascular diseases and DDDIs (p¼ 0.070).
The most frequent DDDIs were related to the con-
comitant use of potassium and either amiloride
(N¼ 12) or spironolactone (N¼ 12). However, 12 resi-
dents concomitantly using potassium and potassium-
sparing diuretics were also administered furosemide.
We also found class DDDIs with the concomitant use
of carbamazepine and risperidone (N¼ 5), felodipin
(N¼ 2), ciclosporin (N¼ 1), quetiapine (N¼ 1), estriol
(N¼ 1), oxycodone (N¼ 1), tolterodine (N¼ 1), or
lercanidipine (N¼ 1). The concomitant use of metho-
trexate and pantoprazole (N¼ 4), omeprazole (N¼ 2),
esomeprazole (N¼ 2), or lansoprazole (N¼ 1) was also
reported. The concomitant use of a calcium-channel
and beta-blockers was observed in 10 residents. Only
three DDDI cases caused by concomitant use of non-
steroidal anti-inflammatory drugs (NSAID) and warfarin
were found (Table 2).
No differences emerged in the three-year all-cause
mortality between the residents exposed to DDDIs and
those not exposed to DDDIs. (46.2% vs. 44.4%,
p¼ 0.76) (Table 1).
Discussion
Of the participating residents in assisted living facilities,
one in 17 had a combination of drugs that should be
avoided, and are thus at risk for class D interactions.
Patients prescribed a higher number of drugs or with
arthritis were associated with more DDDI combinations.
The most commonly identified interacting medication
pairs were potassium with potassium-sparing diuretics,
Table 1. Characteristics of residents in assisted living divided according to their exposure to all class D
drug–drug interactions (DDIs).
Characteristics
Potential for class D
DDI (N¼ 78)
No potential for class D
DDI (N¼ 1249) p Valuee
Demographic characteristics
Age, mean (SD) 82.0 (7.5) 82.8 (7.8) 0.32
Female, % 78.2 78.3 0.98
Widowed, % 62.2 58.6 0.54
Education level, primary school or less, % 56.9 55.7 0.84
Medical conditions
Charlson comorbidity index, mean (SD) 2.9 (1.0) 2.9 (1.1) 0.52
Dementia, % 59.7 59.1 0.91
Prior stroke or transient ischemic attack, % 27.3 25.6 0.75
Diabetes mellitus, % 20.8 17.8 0.51
Coronary heart disease, % 37.7 28.0 0.070
Depression, % 26.0 21.0 0.30
Other psychiatric disorders, % 11.7 10.7 0.79
Parkinson’s disease, % 5.2 5.2 0.99
Rheumatoid arthritis, osteoarthritis, % 24.7 15.4 0.030
COPD or asthma, % 14.3 13.9 0.93
Prior gastric or duodenal ulcer, % 2.6 4.0 0.53
Prior or current cancer, % 10.4 13.7 0.41
Chronic inflammatory disease, % 9.1 7.3 0.56
Prior hip fracture, % 15.6 13.1 0.53
Number of drugs, mean (SD) 10.8 (3.8) 7.9 (3.7) <0.001
Functioning, nutrition and psychological well-being
CDRa, memory class >0.5, % 48.0 55.4 0.21
Dependent on ADLb, CDR ‘‘personal care’’>1% 68.0 68.5 0.92
Nutritional status according to the MNAc 0.96
Well-nourished (>23.5 points), % 23.1 22.4
At risk for malnutrition (17–23 points), % 65.4 64.9
Malnourished (<17 points), % 11.5 12.7
PWBd scale, mean (SD) 0.65 (0.26) 0.68 (0.24) 0.34
Mortality
One-year mortality, % 11.5 14.0 0.54
Three-year mortality, % 46.2 44.4 0.76
aCDR: Clinical Dementia Rating Scale.
bADL: Activities of Daily Living.
cMNA: Mini Nutritional Assessment [22].
dPWB: Psychological well-being [23].
eChi-square test for categorical variables, Mann–Whitney U-test for continuous variables.
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Table 2. Class D drug–drug interactions (DDIs) in assisted living residents in Helsinki and Espoo, Finland.
Drug
Interacting
drug
Residents
exposed to
severe DDIs Concern
Warfarin Aspirin 2 Both warfarin and acetylsalicylic acid interfere with the blood’s coagulation system through dif-
ferent mechanisms, causing an increased risk of bleedings, if combined.
Celecoxib 1 Warfarin inhibits vitamin K-epoxide reductase, while coxibs damage the gastrointestinal
mucosa, probably contributing to an increased risk of gastrointestinal bleeding in warfarin-
treated patients.
Tramadol 2 Tramadol may inhibit platelet aggregation and increase the risk of bleeding.
Verapamil Digoxin 2 Inhibition of P-glycoprotein mediated excretion of digoxin by verapamil followed by significant
increase in serum digoxin levels that may cause digoxin toxicity, asystole and sinus arrest.
Timolol 1 Calcium blockers acting on the SA and AV nodes can interact pharmacodynamically with beta-
blockers, exerting an additive cardiodepressive effect.
Bisoprolol 1 Calcium blockers acting on the SA and AV nodes can interact pharmacodynamically with beta-
blockers, exerting an additive cardiodepressive effect.
Diltiazem Metoprolol 2 Calcium blockers acting on the SA and AV nodes can interact pharmacodynamically with beta-
blockers, exerting an additive cardiodepressive effect.
Atenolol 1
Timolol 2
Propanolol 1
Clopidrogel Esomeprazol 1 Inhibition of CYP2C19 catalyzed clopidrogel bioactivation by esomeprazole or its sulphone
metabolite resulting in loss of clopidrogel efficacy.
Omeprazol 2 Inhibition of CYP2C19 catalyzed clopidrogel bioactivation by omeprazole resulting in loss of
clopidrogel efficacy.
Carbamazepine Risperidone 5 Probably the induction of CYP3A4 catalyzed metabolism of risperidone by carbamazepine fol-
lowed by a decreased plasma risperidone concentration.
Quetiapine 1 Induction of CYP3A4 by carbamazepine and inhibition of epoxide hydrolase and/or glucuroni-
dation by quetiapine, resulting in decreased plasma quetiapin concentration and increased
carbamazepine metabolite and parent compound ratio.
Felodipine 2 Probably the induction of CYP3A4 catalyzed metabolism of felodipine by anticonvulsants result-
ing in loss of felodipin efficacy.
Ciclosporin 1 Probably the induction of ciclosporin hepatic metabolism or a reduced systemic bioavailability
(possible induction of pre-hepatic metabolism) with the concurrent use of carbamazepine
resulting in decreased cyclosporin plasma concentration.
Estriol 1 Induction of P450 enzymes and glucuronidation by carbamazepine decreasing estriol plasma
levels.
Oxycodone 1 Induction of CYP3A4 catalyzed oxycodone metabolism, decreasing oxycodone exposure and
therapeutic effect.
Tolterodine 1 Induction of CYP3A4 catalyzed tolterodine metabolism, decreasing tolterodine exposure and
therapeutic effect.
Lercanidipine 1 Induction of CYP3A4 catalyzed lercanidipine metabolism, decreasing lercanidipine exposure
and therapeutic effect.
Ferroussulfates Doximycin 1 Iron ions form an insoluble complex with doximycin, resulting in reduced absorption of
doximycin.
Norfloxacin 1 Iron ions form an insoluble complex with norfloxacin, resulting in reduced absorption of
norfloxacin
Colestyramine Furosemide 1 Reduced intestinal absorption of furosemide by resins.
Potassium Spironolactone 12 There is an additive effect of potassium supplements and potassium sparing diuretics, which
can result in hyperkalemia.
Amiloride 12
Triamterene 2
Calcium Norfloxacin 2 Calcium impairs the absorption of norfloxacin, probably by forming insoluble chelate
complexes.
Ciprofloxacin 1 Calcium impairs the absorption of ciprofloxacin, probably by forming insoluble chelate
complexes.
Methotrexate Lansopratzole 1 Probably inhibition of the active renal excretion of methotrexate. The risk of methotrexate
intoxication increases in patients treated with high doses of methotrexate.
Pantoprazole 4
Omeprazole 2
Esomeprazole 2
Oxycodone Rifampicin 1 Induction of CYP3A4 catalyzed oxycodone metabolism.
Magnesium Norfloxacin 1 Formation of insoluble chelates occurs between the cations contained in antacids and norfloxa-
cin, resulting in decreased bioavailability of norfloxacin. Furthermore, the solubility of nor-
floxacin decreases at increased pH.
Periciazine Levodopa 1 Classic antipsychotics inhibit dopamine D2-receptors, and may therefore antagonize the thera-
peutic effects of levodopa. Levodopa may weaken the antipsychotic effect of neuroleptics.
Cabergoline 1 Cabergoline is a dopamine D2-receptor agonist. Theoretically, dopamine D2-receptor antago-
nists like antipsychotics may antagonize cabergoline’s therapeutic effect, and vice versa.
Amlodipin Rifampicin 1 Induction of CYP3A4 catalyzed the metabolism of calcium channel blockers resulting in
decreased anti-hypertensive therapeutic effect
Fenytoin Tamsulomin 1 Induction of CYP3A4 catalyzed tamsulosin metabolism by fenytoin resulting in a reduction of
tamsulosin exposure.
(continued)
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methotrexate with proton-pump inhibitors, carbamaze-
pine with various drugs, and calcium-channel blockers
with beta-blockers. DDDIs were not associated with
higher mortality.
The main strength of this study is its large and rep-
resentative geriatric population in an institutionalized
setting with high levels of comorbidities, prevalent
dementia, and the use of a large number of drugs. The
nurses who retrieved the clinical data for the study
had a specific training for the purpose. That strength-
ens the validity of the study. One limitation of the
study is its cross-sectional nature, which does not allow
drawing conclusions on causal relationships between
DDDIs and associated factors. The participation rate of
this study was 67%, which is well in line with compar-
able studies. Unfortunately, we do not have informa-
tion concerning the nonparticipants. Informed consent
could often not be obtained from this group due to
severe dementia and not having a close proxy.
Another limitation is that we have no clinical data on
actual adverse events or hospitalizations. Nor we had
access to medication records after the time of this
study. Possible changes of medication could have
brought about DDDIs and could also have been associ-
ated with mortality. Furthermore, the generalizability of
our study is limited to older people’s care facilities.
The prevalence of DDDIs (5.9%) falls between the
lowest and highest rates presented in earlier studies
(0.7–16%).[1,3,4,6,8] Two of these studies have used
exactly the same criteria (SFINX) for DDDIs,[1,3] and
showed strikingly similar prevalence rates of 5% and
4.8%. Johnell and Klarin’s was a register-based study in
a general older population whereas the study of Hosia-
Randell et al. was performed in an institutional setting.
That study showed that the most common DDDIs were
related to the use of potassium-sparing diuretics,
carbamazepine, and codeine. Compared with residents
not exposed to DDDIs, those exposed to potential
DDDIs were more likely to be younger, to have a prior
history of stroke, to be taking psychotropics, to be
administered nine or more drugs daily and to be tak-
ing potentially inappropriate drugs.[1]
Our results are in line with earlier studies conclud-
ing that a higher number of prescribed drugs increases
the risk of DDDIs.[1–5,11–13] Most studies have
assessed DDDIs but not their outcomes. Only a few
studies have explored the adverse events as conse-
quences of DDDIs.[14,15,24] To our knowledge, our
study is the first one to investigate the association
between DDDIs and mortality. It is somewhat surpris-
ing that no association was observed. Even though
mortality is high in a study population like ours, our
study is underpowered to detect small differences in
mortality between those with DDDIs and those
without.
Cardiovascular diseases [12] and stroke [1] have
been associated with a higher DDDI risk. However, we
found no association between cardiovascular diseases
or stroke and DDDIs in our sample, although a trend
(p¼ 0.07) emerged between coronary heart disease
and DDDIs. This may have clinical implications since
cardiovascular diseases are so common in frail
populations.
The most common DDDIs in previous studies have
been associated with the use of anticoagu-
lants,[10,13,25] potassium-sparing diuretics, potassium
supplements, or angiotensin-converting enzyme (ACE)
inhibitors,[1,3,14] aspirin with other NSAIDs [3] and
carbamazepine with various drugs.[1] Our findings con-
firm that the concomitant use of potassium-sparing
diuretics and potassium supplements are common
DDDIs. Among concomitant users of potassium
Table 2. Continued
Drug
Interacting
drug
Residents
exposed to
severe DDIs Concern
Tramadol Duloxetine 1 Tramadol is a prodrug and the formation of active M1 metabolite by CYP2D6 is a prerequisite
of the opioid effect. Fluoxetine, paroxetine and duloxetin all inhibit this enzyme. The com-
bination may cause serotonin syndrome, as both drugs inhibit serotonin re-uptake, and tra-
madol also increases the release of serotonin.
Felodipine Itraconazole 1 Inhibition of CYP3A4 catalyzed metabolism by itraconazole, following a significant increase in
plasma concentrations of felodipine resulting in hypotension and ankle swelling.
Timolol Acetazolamide 5 Concomitant use may result in dyspnoea and acidosis in patients with pulmonary obstruction
or emphysema.
Duloxetine Codeine 1 Inhibition of CYP2D6 catalysed morphine formation from codeine by duloxetine. In clinical
studies codeine increased the threshold of experimental pain in extensive metabolisers of
CYP2D6 but not of poor metabolisers lacking the activation process. Similarly, the CYP2D6
inhibitor quinidine decreased morphine formation from codeine and reduced the analgesic
effect and abuse liability of codeine. Duloxetine is a moderate CYP2D6 inhibitor. The effect
of duloxetine on the pharmacokinetics or pharmacodynamics of codeine has not been
studied, but it is likely that duloxetine reduces the analgesic effect of codeine in a similar
way as other CYP2D6 inhibitors.
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supplements and potassium-sparing agents in our
study, 12 of them were also administered furosemide,
which might lower potassium levels. This suggests that
the physicians prescribing these drugs may be aware
of these DDDIs. Close potassium follow-up is common
among Finnish residential care patients to prevent
hyperkalemia, and clinical benefits may thus over-
shadow the potential risks of DDDIs.[8] It is important
to estimate whether the benefit of a combination of
drugs outweighs the potential risk of an adverse effect.
In line with a previous study,[1] carbamazepine com-
monly predisposed users to several DDDIs. However,
DDDIs related to the use of anticoagulants was fairly
uncommon in our population.
Our findings suggest that the use of methotrexate
with proton pump-inhibitors (PPIs) may also commonly
predispose users to DDDIs. To our knowledge, this is a
new finding, although the seriousness of the inter-
action potential has been discussed.[1,26] Autoimmune
diseases are common among older people, and metho-
trexate has become a common treatment of these dis-
eases. The small methotrexate doses used in
autoimmune diseases and arthritis may not have clinic-
ally significant interaction with PPIs. The concomitant
use of high methotrexate doses and PPIs is considered
potentially dangerous. None of our participants used
high-dose methotrexate for cancer. The use of PPIs is
very prevalent in institutionalized settings and they are
often used along with NSAIDs.[27] Thus, rheumatoid
arthritis may just be a confounder associated with the
use of both methotrexate and NSAIDs with concomi-
tant PPIs.
DDDI prevalence varies between countries, settings,
and populations. The most common drugs involved in
DDDI also seem to vary over time. Our study suggests
that, e.g. in Finnish institutional settings DDDIs related
to codeine have disappeared between the years 2003
and 2007 [1], whereas potassium-sparing diuretics and
carbamazepine continue to predispose patients to
DDDIs.[1]
The prevalence of DDDIs remained very similar
between the years 2003 and 2007 in Finland, despite
the introduction of the SFINX database during this
period. Automatically alerting software programmes
have been set up for DDDIs, many of which are inte-
grated into clinical decision-support programmes
hopefully contributing to improved healthcare and
decreased costs in older patients.[28] In Sweden,
DDDIs were associated with a 17% decrease of interac-
tions from 2.15 103 to 1.81 103 interactions per
prescribed drug–drug pair by integrating the SFINX
database into primary care electronic health
records.[17] Our study suggests that Finnish physicians
do not fully take advantage of SFINX, which is available
to them but does not automatically alert them. It has
been gradually introduced to physicians and assisted
living facilities since 2005. A study from today, 2015,
could result in different findings, as the SFINX system
is currently more widely used. However, computerized
drug prescribing alerts may improve patient safety, but
are often overridden because of poor specificity and
alert overload.[29–31] At the time of our study, the
assisted living facilities in Helsinki were most often
consulted by temporarily hired physicians. As sug-
gested by geriatricians in their survey, these old, multi-
morbid residents would probably benefit from care by
GPs working continuously with them.[32]
Conclusions
About 6% of frail older people in residential care facili-
ties were exposed to potentially most severe class D
interactions (DDDIs). This exposure was associated with
the use of a high number of drugs, but not with all-
cause mortality or with the degree of psychological
wellbeing. The introduction of drug–drug interaction
database systems has not reduced the prevalence of
DDDIs among residents of assisted living facilities in
2007. Further studies are needed to investigate physi-
cians’ knowledge of and attitudes towards DDDIs and
also the usability of the computerized database system
SFINX for assessing DDDIs.
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